either as new companies or through licensing agreements with pharmaceutical and biotechnology companies.

At the outset, IRAZÚ will leverage innovative biochemical mechanisms described in hypoxia tolerant and neuroprotected phenotypes, including caloric restriction models, newborn mammals and hibernators to promote survival, prevent disease and improve quality of life in old age. The company also holds partnerships in the fields of immuno-oncology and gene therapy. The IRAZÚ model will continue to add new projects emanating from university and federal agencies.